The healthcare sector is one of the industries that is rapidly recovering, and advances in drug research and development are yielding spectacular results. Canada is a global biotechnology leader, with the government assisting in the development of strong, competitive biomanufacturing and life sciences sector, making it a global investment opportunity
Every year, between 250,000 and 500,000 people around the world sustain a spinal cord injury (SCI). Four industry figureheads came together last week to address this challenge in our exclusive roundtable. Catch up now on YouTube or read on for our highlights from the debate. Read More
Each year, hundreds of thousands of people suffer from spinal cord injury. In addition, poor medical care and the lack of availability of effective treatments contribute to an increase in SCI patient mortality and disability. With rising numbers of workplace accidents, road accidents, and other medical conditions, the global SCI
Results show a significant increase in effectiveness of NurExone’s therapeutic compounds in inhibition of PTEN expression Read More
The Future Markets Research Tank (FMRT) is proud to release market commentary on NurExone Biologic (TSXV: NRX) (FSE: J90), an innovative biotechnology company poised to disrupt the spinal cord injury treatment industry and the exosome research landscape Read More
Woher kommt diese Exosome-Technologie? – Wieso gerade jetzt der Börsengang? – Exosome können wir also auch mit Informationen bestücken, wie sie etwas heilen oder reparieren müssen? – Kann man diese Technologie auch gegen Krebs und Tumore verwenden? – Kommen wir zur Querschnittslähmung, hier sind ja die Nervenstränge getrennt. Wie bringe
It is well known that the pandemic caused a sharp rise in the price of tech stocks, which also boosted late-stage startup valuations significantly. This trend benefited startups in many industries, including biotech and e-commerce. In addition to receiving record funding, the number of unicorns increased significantly in 2021 to
NurExone Biologic Ltd. is an Israeli biotech company developing treatment to restore function in patients with traumatic CNS damage. NurExone’s approach is based on a proprietary exosome-based technology with intranasal delivery to revolutionize the treatment of acute spinal cord injury (SCI) worldwide.Read More
Calgary, Alberta–(Newsfile Corp. – September 1, 2022) – NurExone Biologic Inc. (TSXV:NRX) (formerly, EnerSpar Corp. or “EnerSpar”) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, announced today that it agrees to offer 170,195 common shares of the Company at a deemed price
